Comin-Anduix B - Search Results

1

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.

Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Homet Moreno B, et al. Oncoimmunology. 2015 Aug 17;5(7):e1052212. doi: 10.1080/2162402X.2015.1052212. eCollection 2016 Jul. Oncoimmunology. 2015. PMID: 27622011 Free PMC article.

2

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. Koya RC, et al. Cancer Res. 2012 Aug 15;72(16):3928-37. doi: 10.1158/0008-5472.CAN-11-2837. Epub 2012 Jun 12. Cancer Res. 2012. PMID: 22693252 Free PMC article.

3

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.

Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. Lassen A, et al. Mol Cancer. 2014 Apr 16;13:83. doi: 10.1186/1476-4598-13-83. Mol Cancer. 2014. PMID: 24735930 Free PMC article.

4

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.

Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A. Robert L, et al. Oncoimmunology. 2014 Jun 25;3:e29244. doi: 10.4161/onci.29244. eCollection 2014. Oncoimmunology. 2014. PMID: 25083336 Free PMC article.

5

Immunosensitization with a Bcl-2 small molecule inhibitor.

Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. Begley J, et al. Cancer Immunol Immunother. 2009 May;58(5):699-708. doi: 10.1007/s00262-008-0592-4. Epub 2008 Sep 20. Cancer Immunol Immunother. 2009. PMID: 18807035 Free PMC article.

6

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Atefi M, et al. PLoS One. 2011;6(12):e28973. doi: 10.1371/journal.pone.0028973. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194965 Free PMC article.

7

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. Escuin-Ordinas H, et al. Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1. Mol Oncol. 2014. PMID: 24345644 Free PMC article.

8

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Atefi M, et al. Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8. Clin Cancer Res. 2014. PMID: 24812408 Free PMC article.

9

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Wong DJ, et al. Mol Cancer. 2014 Aug 20;13:194. doi: 10.1186/1476-4598-13-194. Mol Cancer. 2014. PMID: 25142146 Free PMC article.

10

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.

Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. Atefi M, et al. Mol Cancer. 2015 Feb 3;14(1):27. doi: 10.1186/s12943-015-0293-5. Mol Cancer. 2015. PMID: 25645078 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page